Hemato-oncology
Risk factors for neutropenic fever in non-Hodgkin’s lymphoma patients with primary granulocyte colony-stimulating factor prophylaxis
Yu Ri Kim, Soo-Jeong Kim, Yong Park, Sung Yong Oh, Hwan-Jung Yun, Yeung-Chul Mun, Jin Seok Kim; the Korean Society of Hematology Lymphoma Working Party
Korean J Intern Med. 2021;36(5):1181-1189. Published online July 16, 2021
Background/Aims: Febrile neutropenia (FN) interferes with the proper chemotherapy dose density or intensity in non-Hodgkin’s lymphoma (NHL) patients. Chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) ± rituximab has an intermediate FN risk. Prophylactic granulocy..
|